DK2148697T3 - Lyofiliseret CPG indeholdende WT-1-sammensætning - Google Patents

Lyofiliseret CPG indeholdende WT-1-sammensætning

Info

Publication number
DK2148697T3
DK2148697T3 DK08759906.4T DK08759906T DK2148697T3 DK 2148697 T3 DK2148697 T3 DK 2148697T3 DK 08759906 T DK08759906 T DK 08759906T DK 2148697 T3 DK2148697 T3 DK 2148697T3
Authority
DK
Denmark
Prior art keywords
composition
cpg containing
lyophilized
lyophilized cpg
cpg
Prior art date
Application number
DK08759906.4T
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/055037 external-priority patent/WO2007137986A2/en
Priority claimed from GB0723044A external-priority patent/GB0723044D0/en
Priority claimed from GB0723900A external-priority patent/GB0723900D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK2148697T3 publication Critical patent/DK2148697T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08759906.4T 2007-05-24 2008-05-22 Lyofiliseret CPG indeholdende WT-1-sammensætning DK2148697T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2007/055037 WO2007137986A2 (en) 2006-05-26 2007-05-24 Vaccination against cancer
GB0723044A GB0723044D0 (en) 2007-11-23 2007-11-23 Lyophillised antigen composition
GB0723900A GB0723900D0 (en) 2007-12-06 2007-12-06 Lyophillised antigen composition
PCT/EP2008/056305 WO2008142133A1 (en) 2007-05-24 2008-05-22 Lyophilised antigen composition

Publications (1)

Publication Number Publication Date
DK2148697T3 true DK2148697T3 (da) 2012-12-17

Family

ID=39714209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08759906.4T DK2148697T3 (da) 2007-05-24 2008-05-22 Lyofiliseret CPG indeholdende WT-1-sammensætning

Country Status (23)

Country Link
US (2) US20090035360A1 (da)
EP (3) EP2148697B1 (da)
JP (1) JP5331105B2 (da)
KR (2) KR20110091817A (da)
CN (1) CN101678091A (da)
AR (1) AR066676A1 (da)
AU (1) AU2008252911B2 (da)
BR (1) BRPI0811228A2 (da)
CA (1) CA2687632C (da)
CL (1) CL2008001491A1 (da)
CY (1) CY1113446T1 (da)
DK (1) DK2148697T3 (da)
EA (3) EA018201B1 (da)
ES (1) ES2395333T3 (da)
HR (1) HRP20121019T1 (da)
MX (1) MX2009012381A (da)
PE (1) PE20090281A1 (da)
PL (1) PL2148697T3 (da)
PT (1) PT2148697E (da)
SI (1) SI2148697T1 (da)
TW (1) TW200911304A (da)
UY (1) UY31101A1 (da)
WO (1) WO2008142133A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2413951A4 (en) 2009-04-03 2015-05-20 Univ Duke FORMULATION FOR GENERATING A WIDE REACTIVE NEUTRALIZATION OF HIV ANTIBODIES
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
CA2841380A1 (en) * 2011-07-22 2013-01-31 Glaxosmithkline Biologicals S.A. Prame purification
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
AU2014388299A1 (en) * 2014-03-25 2016-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
CN110582282A (zh) 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
JP2020536946A (ja) 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
AU2020379738A1 (en) 2019-11-05 2022-04-14 Adjuvance Technologies, Inc. Varicella zoster

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US666A (en) 1838-04-02 Sfbing-bock for coagh and railroad-gab
US5827A (en) 1848-10-03 Improved table-cutlery
CA1339204C (en) 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) * 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
AU745555B2 (en) * 1997-09-25 2002-03-21 Sloan-Kettering Institute For Cancer Research Fucosyl GM1-KLH conjugate vaccine against small cell lung cancer
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1088072A2 (en) 1998-06-22 2001-04-04 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes
ATE315405T1 (de) * 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2000044899A1 (en) 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
EP1165778B1 (en) 1999-03-11 2006-10-18 GlaxoSmithKline Biologicals S.A. Uses of casb618 polynucleotides and polypeptides
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
SI1650221T1 (sl) 2000-02-23 2012-09-28 Glaxosmithkline Biolog Sa Nove spojine
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP4601956B2 (ja) 2001-09-20 2010-12-22 グラクソ グループ リミテッド Hiv−gagのコドン最適化dnaワクチン
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
CA2511625A1 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
MXPA06014581A (es) * 2004-06-12 2007-08-02 Le Ct Nat De La Rech Scient Cn Metodo para mejorar la respuesta inmune a una vacuna.
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1858526A1 (en) 2005-03-02 2007-11-28 Solbec Pharmaceuticals Limited Glycoalkaloid and tlr agonist combinations and various uses thereof
EP2385059A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Also Published As

Publication number Publication date
MX2009012381A (es) 2009-12-01
US20110059163A1 (en) 2011-03-10
EA018201B1 (ru) 2013-06-28
EP2148697A1 (en) 2010-02-03
EP2148697B1 (en) 2012-10-03
EP2476431A1 (en) 2012-07-18
CA2687632A1 (en) 2008-11-27
JP2010527964A (ja) 2010-08-19
JP5331105B2 (ja) 2013-10-30
US20090035360A1 (en) 2009-02-05
ES2395333T3 (es) 2013-02-12
AR066676A1 (es) 2009-09-02
EA200901434A1 (ru) 2010-06-30
KR20100017519A (ko) 2010-02-16
PL2148697T3 (pl) 2013-02-28
TW200911304A (en) 2009-03-16
KR20110091817A (ko) 2011-08-12
CY1113446T1 (el) 2016-06-22
US8557247B2 (en) 2013-10-15
PT2148697E (pt) 2012-12-24
SI2148697T1 (sl) 2013-01-31
BRPI0811228A2 (pt) 2014-10-21
WO2008142133A1 (en) 2008-11-27
UY31101A1 (es) 2009-01-05
AU2008252911B2 (en) 2013-09-05
HRP20121019T1 (hr) 2013-01-31
AU2008252911A1 (en) 2008-11-27
CL2008001491A1 (es) 2008-11-28
EP2489367A1 (en) 2012-08-22
PE20090281A1 (es) 2009-03-28
EA201300102A1 (ru) 2014-02-28
CN101678091A (zh) 2010-03-24
EA201300101A1 (ru) 2014-02-28
KR101238795B1 (ko) 2013-03-07
CA2687632C (en) 2013-01-15

Similar Documents

Publication Publication Date Title
NL301210I1 (nl) Avalglucosidase alfa
NO2020033I1 (no) andeksanet alfa
SI2148697T1 (sl) Liofilizirani sestavek, ki vsebuje CpG in WT-1
BRPI0813775A2 (pt) Composição
DE602007011030D1 (de) Gummizusammensetzung
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
ME01423B (me) Fungicidni sastavi
HUE059171T2 (hu) Kompozíciók
PT2596784T (pt) Composições de tapentadol
HRP20170963T1 (hr) Modificirani saharidi
BRPI0810557A2 (pt) composição
BRPI0815246A2 (pt) Composição de catalisador
BRPI0811274A2 (pt) Composição
BRPI0821841A2 (pt) Composição de borracha
BRPI0811939A2 (pt) Tiazóis substituídos por heteroarila
EP2177564A4 (en) ACRYLIC ELASTOMER COMPOSITION
EP2144635A4 (en) STERILIZING COMPOSITION
DE602008000522D1 (de) Dissektionsvorrichtung
PT2182988E (pt) Composição radiofarmacêutica
BRPI0820252A2 (pt) composição compreendendo arbutina
BRPI0811002A2 (pt) Composição biofertilizante
NO2022038I1 (no) ropeginterferon alfa-2b
DK2133416T3 (da) Rekombinant mikroorganisme
BRPI0820960A2 (pt) composição
IT1393655B1 (it) Composizione pesticida